Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$13.27+0.17 (+1.30%)
Close on Nov 13, 2026Market cap $1.72BP/E –Yield –
Mesoblast total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Mesoblast's total debt was $129.83M at Jun 30, 2026. For fiscal 2026 it was $129.83M, down 26.3% from the year before. The highest annual figure on record is $176.05M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $129.83M | -26.3% |
| FY2025 | Jun 30, 2025 | $176.05M | +37.3% |
| FY2024 | Jun 30, 2024 | $128.21M | +11.8% |
| FY2023 | Jun 30, 2023 | $114.72M | +12.9% |
| FY2022 | Jun 30, 2022 | $101.65M | -31.1% |
| FY2021 | Jun 30, 2021 | $147.45M | +20.9% |
| FY2020 | Jun 30, 2020 | $121.93M | +28.0% |
| FY2019 | Jun 30, 2019 | $95.29M | +60.4% |
| FY2018 | Jun 30, 2018 | $59.40M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $129.83M | +1.3% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $193.61M | +55.8% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $176.05M | +53.5% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $136.49M | +28.3% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $128.21M | +17.8% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $124.30M | +18.2% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $114.72M | +12.9% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $106.36M | +6.7% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $108.86M | +12.3% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $105.16M | -30.1% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $101.65M | -31.1% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $99.69M | -31.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $96.95M | -26.7% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $150.35M | +19.4% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $147.45M | +20.9% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $145.19M | +27.4% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $132.23M | +27.3% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $125.88M | +22.7% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $121.93M | +28.0% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $113.95M | +28.1% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $103.85M | +56.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $102.58M | +72.7% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $95.29M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $88.94M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $66.58M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $59.40M | – |
See a number that looks wrong?